Emerging CAR T cell strategies for the treatment of AML
P Vishwasrao, G Li, JC Boucher, DL Smith, SK Hui - Cancers, 2022 - mdpi.com
Simple Summary Chimeric antigen receptors (CARs) targeting CD19 have emerged as a
new treatment for hematological malignancies. As a “living therapy”, CARs can precisely …
new treatment for hematological malignancies. As a “living therapy”, CARs can precisely …
Biomarkers as targets for CAR-T/NK cell therapy in AML
R Shao, Z Li, H Xin, S Jiang, Y Zhu, J Liu, R Huang… - Biomarker …, 2023 - Springer
The most common kind of acute leukemia in adults is acute myeloid leukemia (AML), which
is often treated with induction chemotherapy regimens followed by consolidation or …
is often treated with induction chemotherapy regimens followed by consolidation or …
Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia
Acute myeloid leukemia (AML) is a hostile hematological malignancy under great danger of
relapse and poor long-term survival rates, despite recent therapeutic advancements. To deal …
relapse and poor long-term survival rates, despite recent therapeutic advancements. To deal …